Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology.
The last earnings update was 81 days ago.
Discounted Cash Flow Calculation for TSXV:HXI using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method. We use
analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
TSXV:HXI DCF 1st Stage: Next 5 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
HooXi Network's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HooXi Network has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare HooXi Network's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare HooXi Network's earnings growth to the Canada market average as no estimate data is available.
Unable to compare HooXi Network's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if HooXi Network is high growth as no earnings estimate data is available.
Unable to determine if HooXi Network is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
HooXi Network's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Yun Zhu, also known as Avis, serves as Chief Executive Officer and Director at HooXi Network Inc. since October 9, 2018. Ms. Zhu serves as Chief Marketing Officer of Seven Stars Media Limited. Ms. Zhu has over 20 years of experience in media, public relations and brand management. Prior to joining Seven Stars Media Limited, she served as Vice President of Sun Media Group, Chief Editor for the Chinese version of French Women's magazine Madame Figaro and worked as editor for Figaro Girl. Prior to this, Ms. Zhu served as Chief Editor for iLook Magazine. He serves as CEO at Sun Medical Group since 2016 and served as VP & CMO of Seven Stars Culture Group from 2011 until 2016.
Insufficient data for Avis to compare compensation growth.
Avis's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the HooXi Network management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Director
President & Director
Chief Financial Officer
Medical Advisor & Director
Chief Technology Officer
Chief Medical Officer
Business Development Consultant
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the HooXi Network board of directors is less than 3 years, this suggests a new board.
Do Institutions Own Liberty Biopharma Inc (CVE:HXI) Shares?
A look at the shareholders of Liberty Biopharma Inc (CVE:HXI) can tell us which group is most powerful. … With a market capitalization of CA$9.7m, Liberty Biopharma is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Liberty Biopharma
Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.